

New Zealanders for
HEALTH RESEARCH

Ngā Tāngata o Aotearoa
mō te Rangahau Hauora

النيوزيلنديون للبحوث الصحية

Clinical trials yesterday today and tomorrow

HEALTH AND PROSPERITY THROUGH CLINICAL TRIALS

22nd MARCH 2019

Chris Higgins

NZHR Chief Executive

OVERVIEW

- Workshop purpose and programme
- Milestones
- Trends
- NZHR 2017 workshop outcomes
- Where to from here?

MILESTONES

- Health Committee review of clinical trials 2011
- Health Research Strategy 2017
- Government R&D investment strategy 2018
- NEAC health research standards review 2018/19
- Therapeutic products legislation 2019

HEALTH COMMITTEE REVIEW

- Implementation has been limited, slow and patchy
- Recommendations not supported and not progressed:
 - bring New Zealand's investment in health R&D up to international benchmarks
 - establish an innovation fund for co-sponsoring clinical trials with pharmaceutical companies
 - DHBs be funded to undertake clinical research as a front-line activity

HEALTH RESEARCH STRATEGY

- Develop and sustain a strong health research workforce
- Strengthen health sector participation in research and innovation
- Strengthen the clinical research environment and health services research
- Enable and embed translation across the health sector
- Support transformative and innovative ideas
- Create more industry partnerships
- Strengthen platforms for commercialising innovations


R&D INVESTMENT STRATEGY

- 10 year R&D expenditure aspiration set at 2.0% of GDP; NZHR recommendation = 3.3
- tax incentive set at 15% of eligible expenditure; NZHR recommendation = 35%
- CRIs, DHBs, and tertiary education organisations ineligible



THERAPEUTIC PRODUCTS LEGISLATION

- A clinical trial of any therapeutic product would be a controlled activity requiring an authorisation
- Medical device and cell and tissue researchers will work within a regulated trial environment.
- All clinical trials of a medicine would require approval.
- Ethics approval would be legally required for authorised trials
- A comprehensive record of all clinical trials conducted in New Zealand

No of clinical trials in NZ 2008 - 2021




industry funded/sponsored clinical trials 2008 - 2021




New Zealanders for
HEALTH RESEARCH



Drug trials in New Zealand 2009 - 2021



international pharma funded clinical trials in NZ 2008 - 2021





NZ device trials 2008 - 2021




New Zealanders for
HEALTH RESEARCH

NZ% of NZ+AUS total industry funded clinical trials 2008 - 2021



NZ hospital sponsored trials 2008 - 2021



NZHR WORKSHOP 2017

- public awareness campaign to promote participation in clinical trials
- mandating publicly funded health service provider commitment to health research and clinical trials
- publicly funded health service provider workforce development to create research capacity
- clinician discussion about clinical trials being a routine aspect of patient care
- ACC coverage to be extended to harm resulting from clinical trials

IMPORTANCE OF CLINICAL TRIALS

NZ

important to be able to participate

79%

as important as giving blood

62%

more opportunities to participate

66%

USA

as important as giving blood

75%

Roy Morgan Research NZHR opinion poll May 2018
Research America! survey July 2017



New Zealanders for
HEALTH RESEARCH

WILLING TO PARTICIPATE IN A CLINICAL TRIAL OF A NEW MEDICINE

NZ

(“if had a condition it might be able to treat”)

2017

78%

2018

83%

USA

(“if asked by someone I trust”)

74%

Roy Morgan Research NZHR opinion poll May 2018
Research America! survey July 2017

CLINICAL TRIAL PARTICIPATION

NZ
("you")

been asked to participate

14%

ever participated

8%

currently participating

2%

USA

("you and your family ")

ever participated

18%

Roy Morgan Research NZHR opinion poll May 2018
Research America! survey July 2017



New Zealanders for
HEALTH RESEARCH

WHERE TO?



Patients

- World leading clinical care
- Best patient outcomes
- Access to latest treatments
- Increased level of care from participation in trials
- Access to comparator arm drugs




Healthcare Sector

- Clinicians accessing international best practice
- Increased quality - systems and care
- Better patient outcomes
- Increased workforce satisfaction
- Direct and indirect cost savings
- NZ's diversity represented in new drug data



Infrastructure

- Implement clinical research KPIs for DHBs
- Address NZ's treatment injury compensation framework
- Economic growth incentives
- Support clinical research workforce development
- Maintain NZ's speed to start up - ethics
- Consider NZ's reimbursement priorities



WHERE TO?

1. Establishment of a national framework for clinical trial research at district health boards, PHOs and other publicly funded health service entities
2. Set health research/clinical trials specific investment benchmarks and targets
3. Develop clinical trials investment strategies which will enable New Zealand to be competitive with Australia (and other countries) as a place to conduct clinical trials
4. Set targets and develop strategies which will result in public health providers, including DHBs, attracting increased industry investment in clinical trials, especially drug trials
5. District health boards and other publicly funded health service providers be funded to undertake clinical research as a front-line activity
6. Establishment and maintenance of a single accessible register of clinical trials in New Zealand, with sufficient utility, including fields, to enable key elements of clinical trials trends to be reliably analysed and monitored
7. Promote participation in clinical trials through public and physician awareness raising strategies

THANK YOU!

